270 related articles for article (PubMed ID: 33117686)
1. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
Luo Y; Jiang H; Xu W; Wang X; Ma B; Liao T; Wang Y
Front Oncol; 2020; 10():549882. PubMed ID: 33117686
[No Abstract] [Full Text] [Related]
2. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
Yang J; Gong Y; Yan S; Chen H; Qin S; Gong R
Endocrine; 2020 Jan; 67(1):44-57. PubMed ID: 31655978
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
5. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
6. Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.
Su X; Jiang X; Wang W; Wang H; Xu X; Lin A; Teng X; Wu H; Teng L
Onco Targets Ther; 2016; 9():6965-6976. PubMed ID: 27956840
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.
Yin DT; Yu K; Lu RQ; Li X; Xu J; Lei M; Li H; Wang Y; Liu Z
Clin Endocrinol (Oxf); 2016 Aug; 85(2):299-305. PubMed ID: 26732020
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.
Wang Z; Chen JQ; Liu JL; Qin XG
Eur J Clin Invest; 2016 Feb; 46(2):146-57. PubMed ID: 26648183
[TBL] [Abstract][Full Text] [Related]
10. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis.
Vuong HG; Long NP; Anh NH; Nghi TD; Hieu MV; Hung LP; Nakazawa T; Katoh R; Kondo T
Endocr Connect; 2018 Dec; 7(12):R286-R293. PubMed ID: 30352403
[TBL] [Abstract][Full Text] [Related]
11. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
12. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
14. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
Ma YJ; Deng XL; Li HQ
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
Feng G; Luo Y; Zhang Q; Zeng F; Xu J; Zhu J
Endocrine; 2020 Apr; 68(1):56-63. PubMed ID: 31955344
[TBL] [Abstract][Full Text] [Related]
16. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
[TBL] [Abstract][Full Text] [Related]
17. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis.
Vuong HG; Duong UNP; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
World J Surg; 2018 Apr; 42(4):1005-1017. PubMed ID: 28913696
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region.
Passler C; Scheuba C; Prager G; Kaczirek K; Kaserer K; Zettinig G; Niederle B
Endocr Relat Cancer; 2004 Mar; 11(1):131-9. PubMed ID: 15027890
[TBL] [Abstract][Full Text] [Related]
20. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]